IMVT - CIK 0001764013
The table below shows Immunovant, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $994.52M | $521.87M | $598.91M | $374.69M | $472.94M | $560.00M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $1.64M | $1.97M | $1.94M | $2.22M | $1.88M | $2.42M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $1.04B |
| $573.55M |
| $651.76M |
| $412.54M |
| $507.37M |
| $589.05M |
| Property, plant & equipment | $531.00K | $632.00K | $737.00K | $752.00K | $671.00K | $565.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.05B | $582.96M | $661.44M | $420.93M | $515.71M | $589.68M |
| Accounts payable | $8.62M | $6.92M | $7.84M | $19.82M | $20.73M | $11.04M |
| Total current liabilities | $66.26M | $63.25M | $52.90M | $68.31M | $66.65M | $45.02M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $66.26M | $63.25M | $52.90M | $68.31M | $66.65M | $45.02M |
| Retained earnings | -$1.60B | -$1.49B | -$1.36B | -$1.13B | -$1.02B | -$912.83M |
| Total equity | $986.13M | $519.71M | $608.54M | $352.62M | $449.05M | $544.66M |